FSIP1 Is Associated with Poor Prognosis and Can Be Used to Construct a Prognostic Model in Gastric Cancer

Table 2

Univariate and multivariate analyses of FSIP1 expression and clinicopathological characteristics for prognosis.

Characteristics	Total ()	Univariate analysis		Multivariate analysis
		Hazard ratio (95% CI)	value	Hazard ratio (95% CI)	value
FSIP1 expression	166
High group	63	Reference
Low group	103	0.143 (0.069-0.295)	<0.001	0.352 (0.156-0.796)	0.012
Age	166	1.031 (0.997-1.066)	0.072
Sex	166
Male	124	Reference
Female	42	0.400 (0.156-1.026)	0.057
^a T classification	166
T2	25	Reference
T3	78	0.109 (0.033-0.357)	<0.001	0.240 (0.061-0.945)	0.041
T1	53	0.078 (0.011-0.573)	0.012	0.201 (0.025-1.619)	0.132
T4	10	1.169 (0.411-3.325)	0.769	0.302 (0.067-1.355)	0.118
^b N classification	166
N0	75	Reference
N2	29	4.041 (1.504-10.854)	0.006	2.212 (0.769-6.363)	0.141
N3	35	8.696 (3.640-20.773)	<0.001	3.830 (1.306-11.231)	0.014
N1	27	1.178 (0.305-4.554)	0.813	0.667 (0.137-3.236)	0.615
BMI	166	0.921 (0.831-1.021)	0.118
NLR	166	1.073 (0.899-1.280)	0.435
PLR	166	1.003 (0.998-1.008)	0.217
CD4	166	0.973 (0.933-1.015)	0.210
CD8	166	1.042 (1.003-1.083)	0.036	1.044 (0.999-1.092)	0.054
CA19-9	166	1.002 (1.001-1.003)	<0.001	1.001 (1.000-1.003)	0.132
CA72-4	166	1.004 (0.996-1.012)	0.359
CA125	166	1.035 (1.007-1.063)	0.014	1.023 (0.997-1.050)	0.085
Location	166
U	15	Reference
M	41	0.225 (0.075-0.671)	0.007	0.416 (0.130-1.337)	0.141
L	108	0.336 (0.144-0.786)	0.012	0.467 (0.169-1.287)	0.141
Entire	2	4.126 (0.829-20.534)	0.083	4.271 (0.675-27.019)	0.123
WHO classification	166
Well to moderate differentiated	75	Reference
Mucinous	13	2.404 (0.879-6.573)	0.087
Poor differentiated	37	0.467 (0.156-1.396)	0.173
Signet ring cell	41	1.643 (0.790-3.416)	0.184
Vascular invasion	166
Negative	139	Reference
Positive	27	1.848 (0.874-3.907)	0.108
Neural invasion	166
Positive	73	Reference
Negative	93	0.327 (0.167-0.639)	0.001	1.560 (0.609-3.995)	0.354

^ab Based on the 8^th of the AJCC Cancer Staging Manual of the American Joint Committee on Cancer.